JP6240611B2 - Ｔｄｐ−４３に特異的な結合分子 - Google Patents

Ｔｄｐ−４３に特異的な結合分子 Download PDF

Info

Publication number
JP6240611B2
JP6240611B2 JP2014537750A JP2014537750A JP6240611B2 JP 6240611 B2 JP6240611 B2 JP 6240611B2 JP 2014537750 A JP2014537750 A JP 2014537750A JP 2014537750 A JP2014537750 A JP 2014537750A JP 6240611 B2 JP6240611 B2 JP 6240611B2
Authority
JP
Japan
Prior art keywords
tdp
antibody
seq
antibodies
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014537750A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015505665A5 (https=
JP2015505665A (ja
Inventor
ローガー ニッチ，
ローガー ニッチ，
クリストフ ホック，
クリストフ ホック，
モントラシオ， マリア グラジア バレンコ
モントラシオ， マリア グラジア バレンコ
ファビオ モントラシオ，
ファビオ モントラシオ，
ヤン グリム，
ヤン グリム，
ジャン−リュ ベリスヴィル，
ジャン−リュ ベリスヴィル，
ポール ワインレブ，
ポール ワインレブ，
ヤナキ クーマラスワミ，
ヤナキ クーマラスワミ，
オマール キンテロ−モンソン，
オマール キンテロ−モンソン，
Original Assignee
バイオジェン インターナショナル ニューロサイエンス ゲーエムベーハー
バイオジェン インターナショナル ニューロサイエンス ゲーエムベーハー
ユニバーシティー オブ チューリッヒ
ユニバーシティー オブ チューリッヒ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオジェン インターナショナル ニューロサイエンス ゲーエムベーハー, バイオジェン インターナショナル ニューロサイエンス ゲーエムベーハー, ユニバーシティー オブ チューリッヒ, ユニバーシティー オブ チューリッヒ filed Critical バイオジェン インターナショナル ニューロサイエンス ゲーエムベーハー
Publication of JP2015505665A publication Critical patent/JP2015505665A/ja
Publication of JP2015505665A5 publication Critical patent/JP2015505665A5/ja
Application granted granted Critical
Publication of JP6240611B2 publication Critical patent/JP6240611B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Food Science & Technology (AREA)
  • Optics & Photonics (AREA)
  • Psychology (AREA)
JP2014537750A 2011-10-28 2012-10-26 Ｔｄｐ−４３に特異的な結合分子 Expired - Fee Related JP6240611B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161553113P 2011-10-28 2011-10-28
US61/553,113 2011-10-28
PCT/IB2012/002905 WO2013061163A2 (en) 2011-10-28 2012-10-26 Tdp-43 specific binding molecules

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017126314A Division JP6417451B2 (ja) 2011-10-28 2017-06-28 Ｔｄｐ−４３に特異的な結合分子

Publications (3)

Publication Number Publication Date
JP2015505665A JP2015505665A (ja) 2015-02-26
JP2015505665A5 JP2015505665A5 (https=) 2015-10-29
JP6240611B2 true JP6240611B2 (ja) 2017-11-29

Family

ID=47720540

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014537750A Expired - Fee Related JP6240611B2 (ja) 2011-10-28 2012-10-26 Ｔｄｐ−４３に特異的な結合分子
JP2017126314A Expired - Fee Related JP6417451B2 (ja) 2011-10-28 2017-06-28 Ｔｄｐ−４３に特異的な結合分子
JP2018174683A Expired - Fee Related JP6652609B2 (ja) 2011-10-28 2018-09-19 Ｔｄｐ−４３に特異的な結合分子

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2017126314A Expired - Fee Related JP6417451B2 (ja) 2011-10-28 2017-06-28 Ｔｄｐ−４３に特異的な結合分子
JP2018174683A Expired - Fee Related JP6652609B2 (ja) 2011-10-28 2018-09-19 Ｔｄｐ−４３に特異的な結合分子

Country Status (18)

Country Link
US (3) US9587014B2 (https=)
EP (2) EP2771359B1 (https=)
JP (3) JP6240611B2 (https=)
KR (2) KR101961508B1 (https=)
CN (1) CN104159918B (https=)
AU (1) AU2012327211C9 (https=)
BR (1) BR112014010161B1 (https=)
CA (2) CA2853412C (https=)
CL (1) CL2014001074A1 (https=)
EA (1) EA032003B1 (https=)
ES (1) ES2883212T3 (https=)
IL (2) IL232219B (https=)
MX (2) MX357678B (https=)
MY (1) MY167795A (https=)
PH (1) PH12014500940A1 (https=)
SG (1) SG11201401735WA (https=)
WO (1) WO2013061163A2 (https=)
ZA (1) ZA201403680B (https=)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20140049T1 (hr) 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
CA2853412C (en) 2011-10-28 2021-05-04 University Of Zurich Tdp-43 specific binding molecules
CA2914831C (en) * 2013-06-11 2022-10-11 Paul Scherrer Institut Method for determining mutateable ligand-gpcr binding at single amino acid resolution and pairs of mutated ligand and gpcr
WO2015117088A2 (en) 2014-01-31 2015-08-06 Arizona Board Of Regents On Behalf Of Arizona State University Antibody based reagents that specifically recognize neurodegenerative disease related forms of the protein tdp-43
EP4406549A3 (en) 2014-07-29 2025-01-08 Neurimmune Holding AG Human-derived anti-huntingtin (htt) antibodies and uses thereof
CN104497121A (zh) * 2014-08-29 2015-04-08 苏州顺升桥生物科技有限公司 淀粉样蛋白tdp-43及其用途
EP3200825A4 (en) 2014-10-03 2018-03-21 Academia Sinica Antibodies against pathological forms of tdp-43 and uses thereof
WO2016053610A1 (en) * 2014-10-03 2016-04-07 Academia Sinica Antibodies against pathological forms of tdp-43 and uses thereof
TWI592423B (zh) * 2014-10-03 2017-07-21 中央研究院 可辨識致病性ｔｄｐ－４３之抗體及其用途
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
US10509045B2 (en) 2015-05-29 2019-12-17 University Of Florida Research Foundation, Incorporated Methods for diagnosing Huntington's disease
WO2017111166A1 (ja) * 2015-12-25 2017-06-29 国立大学法人東京農工大学 Ｔｄｐ－４３細胞内存在量関連疾患治療剤
DK3430397T3 (da) 2016-03-14 2022-05-02 Biogen Int Neuroscience Gmbh Antistofafhængig cellemedieret fagocytoseassay til pålidelig måling af optagelse af aggregerede proteiner
US10940161B2 (en) 2016-04-04 2021-03-09 University Of Florida Research Foundation, Incorporated Manipulation of EIF3 to modulate repeat associated non-ATG (RAN) translation
US20190330318A1 (en) 2016-07-25 2019-10-31 Biogen Ma Inc. Anti-hspa5 (grp78) antibodies and uses thereof
MA47163A (fr) 2016-12-16 2019-11-06 Biogen Ma Inc Facteur 11 de différenciation de croissance activé protéolytiquement stabilisé
KR102715540B1 (ko) 2017-03-14 2024-10-08 파이브 프라임 테라퓨틱스, 인크. 산성 pH에서 VISTA에 결합하는 항체
WO2018195110A1 (en) 2017-04-17 2018-10-25 University Of Florida Research Foundation, Incorporated Regolation of ran translation by pkr and eif2a-p pathways
CA3064785A1 (en) * 2017-05-30 2018-12-06 The University Of British Columbia Epitopes in the rna recognition motif 1 (rrm1) of tdp-43 and misfolding-selective antibodies thereto
IL272773B2 (en) 2017-08-22 2024-06-01 Biogen Ma Inc Pharmaceutical preparations containing anti-amyloid cell antibodies
JP2020535448A (ja) 2017-09-25 2020-12-03 ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． Ｒａｎタンパク質の検出のための免役アッセイ
US11246857B2 (en) * 2017-12-14 2022-02-15 The Johns Hopkins University Anti-fungal inhibitors
WO2019113711A1 (en) 2017-12-14 2019-06-20 University Of Ottawa Exosome packaging and targeted autophagy
EP3735422A1 (en) * 2018-01-05 2020-11-11 AC Immune SA Misfolded tdp-43 binding molecules
US12215142B2 (en) 2018-03-16 2025-02-04 National University Corporation Shiga University Of Medical Science Antibody fragment degrading and removing abnormal TDP-43
BR112020019083A2 (pt) 2018-03-21 2020-12-29 Five Prime Therapeutics, Inc. Anticorpos, ácido nucleico, composições, célula e métodos para preparar um anticorpo, para tratar câncer, para tratar uma doença infecciosa, para tratar uma inflamação, para a identificação de um anticorpo, para melhorar a eficácia antitumoral de um anticorpo, para melhorar a farmacocinética de um anticorpo, para selecionar um anticorpo, para melhorar a eficácia de anticorpos, para isolar anticorpos, para detectar vista em uma amostra e para tratar câncer
TW202019398A (zh) * 2018-06-28 2020-06-01 張翔毓 用於治療或預防構形疾病之方法及藥物篩選方法
BR112021000303A2 (pt) 2018-07-11 2021-04-13 Five Prime Therapeutics, Inc. Anticorpos que se ligam a vista em ph ácido
CN113508135A (zh) 2018-10-29 2021-10-15 比奥根Ma公司 增强血脑屏障转运的人源化和稳定化的fc5变体
AU2019399680A1 (en) * 2018-12-14 2021-07-15 Promis Neurosciences Inc. Antibodies to misfolded TDP-43 and methods of use
KR20220012270A (ko) * 2019-05-23 2022-02-03 에이씨 이뮨 에스.에이. 항-tdp-43 결합 분자 및 이의 용도
JP7850066B2 (ja) * 2019-08-12 2026-04-22 セロシア セラピューティクス プロプライアタリー リミティド 治療のための組成物および方法
WO2021055880A1 (en) 2019-09-20 2021-03-25 University Of Florida Researchfoundation, Incorporated Detection of antibodies against ran proteins from serum and tissue lysates
GB202004863D0 (en) * 2020-04-02 2020-05-20 Univ Oxford Innovation Ltd Method
BR112022021604A2 (pt) 2020-04-28 2022-12-06 Sola Biosciences Llc Composições e métodos para tratamento de proteinopatias associadas à tdp-43
CA3176840A1 (en) * 2020-04-29 2021-11-04 Neil R. Cashman Single chain antibodies and intrabodies to misfolded tdp-43 and methods of use
US20230288432A1 (en) * 2020-07-06 2023-09-14 The Board Of Regents Of The University Of Texas System Tdp-43 biosensor cell lines
EP4196162A1 (en) * 2020-08-14 2023-06-21 AC Immune SA Humanized anti-tdp-43 binding molecules and uses thereof
JP2023551542A (ja) 2020-11-30 2023-12-08 エニグマ バイオインテリジェンス，インコーポレイテッド アルツハイマー病の非侵襲的評価
MX2023008744A (es) 2021-01-29 2023-10-02 Illimis Therapeutics Inc Molecula de fusion que tiene actividad no inflamatoria inductora de la fagocitosis.
CN112920264B (zh) * 2021-02-08 2022-07-05 武汉大学 Tdp-43蛋白的o-糖基化突变体及其应用
JP6961278B1 (ja) * 2021-03-10 2021-11-05 国立研究開発法人量子科学技術研究開発機構 生体試料中のｔｄｐ−４３を測定する方法及び装置
CA3221254A1 (en) * 2021-05-27 2022-12-01 Mayo Foundation For Medical Education And Research Methods and materials for treating proteinopathies
US20230107901A1 (en) * 2021-10-01 2023-04-06 University Of Utah Research Foundation Pathologic tdp-43 as a biomarker for the diagnosis of tdp-43 proteinopathy
WO2023099788A1 (en) 2021-12-03 2023-06-08 Neurimmune Ag Novel potency assay for antibody-based drugs and useful means therefor
CR20240378A (es) 2022-02-16 2024-10-03 Ac Immune Sa Moléculas de unión anti -tdp-43 humanizadas y usos de las mismas
EP4504775A1 (en) * 2022-04-08 2025-02-12 AC Immune SA Anti-tdp-43 binding molecules
WO2023205579A1 (en) * 2022-04-18 2023-10-26 The Regents Of The University Of California Compositions and methods for disrupting pathological aggregates
EP4497826A4 (en) 2022-04-22 2026-03-25 Univ Niigata TDP-43 AGGREGATION SUPPRESSANT AND PHARMACEUTICAL COMPOSITION
WO2024184494A1 (en) 2023-03-08 2024-09-12 Ac Immune Sa Anti-tdp-43 binding molecules and uses thereof
EP4716540A1 (en) * 2023-06-20 2026-04-01 The Trustees of Dartmouth College Chimeric antigen receptors (cars) targeting tdp43, tregs expressing said cars, and use thereof for the treatment of als, ftd and ad
KR102859015B1 (ko) * 2023-07-20 2025-09-12 충북대학교 산학협력단 ｃ­Ａｂｌ에 의한 ＴＤＰ­４３의 특이적 인산화 분석을 통한 신경퇴행성 질환을 진단하는 방법 및 이를 이용한 신경퇴행성 질환의 치료제 스크리닝 방법
CN116875738A (zh) * 2023-07-24 2023-10-13 山东省农业科学院畜牧兽医研究所 一种鉴定牛tdp-43基因启动子活性区域的方法
AR133828A1 (es) * 2023-09-15 2025-11-05 Prothena Biosciences Ltd Anticuerpos anti-tdp-43 y sus usos
WO2025186332A1 (en) 2024-03-05 2025-09-12 Ac Immune Sa Vectorized anti-tdp-43 antibodies
WO2026013218A1 (en) 2024-07-10 2026-01-15 Ac Immune Sa Anti-tdp-43 vectors, binding molecules and uses thereof
KR20260044274A (ko) * 2024-09-23 2026-04-02 주식회사 피플바이오 Tdp-43에 특이적으로 결합하는 항체 및 이의 용도
CN119331085B (zh) * 2024-10-16 2025-03-14 中国科学院合肥物质科学研究院 沙贝冠状病毒广谱中和抗体及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688511A (en) * 1991-11-05 1997-11-18 Board Of Regents, The University Of Texas System Cellular protein TDP-43 and regulation of HIV-1 gene expression
CA2253633A1 (en) 1997-12-03 1999-06-03 Boehringer Mannheim Corporation Complex specific antibodies, method of preparation and uses thereof
US8354236B2 (en) * 2006-09-29 2013-01-15 The Trustees Of The University Of Pennsylvania Detection of neurodegenerative disease
KR20120017469A (ko) * 2007-01-05 2012-02-28 유니버시티 오브 취리히 질환 특이적 결합 분자 및 표적을 제공하는 방법
WO2008151055A1 (en) 2007-06-01 2008-12-11 Mayo Foundation For Medical Education And Research Diagnosing neurodegenerative diseases
WO2009008529A1 (ja) 2007-07-06 2009-01-15 Tokyo Metropolitan Organization For Medical Research Ｔｄｐ－４３凝集物に特異的に結合する抗体
CA2713871C (en) 2008-02-01 2018-05-22 Washington University In St. Louis Sequences associated with tdp-43 proteinopathies and methods of using the same
AU2009328505B2 (en) 2008-12-19 2014-11-27 Panima Pharmaceuticals Ag Human anti-alpha-synuclein autoantibodies
CN101634656A (zh) 2009-08-21 2010-01-27 武汉三鹰生物技术有限公司 人tdp-43的单抗包被酶标板的制法及elisa检测试剂盒
CA2853412C (en) 2011-10-28 2021-05-04 University Of Zurich Tdp-43 specific binding molecules

Also Published As

Publication number Publication date
HK1201846A1 (en) 2015-09-11
EP3964524A1 (en) 2022-03-09
EP2771359A2 (en) 2014-09-03
US10259866B2 (en) 2019-04-16
KR20140100480A (ko) 2014-08-14
JP6417451B2 (ja) 2018-11-07
ZA201403680B (en) 2020-05-27
JP2015505665A (ja) 2015-02-26
AU2012327211B2 (en) 2016-03-10
WO2013061163A2 (en) 2013-05-02
JP2017205118A (ja) 2017-11-24
NZ624871A (en) 2016-06-24
SG11201401735WA (en) 2014-05-29
CA2853412C (en) 2021-05-04
MY167795A (en) 2018-09-26
BR112014010161A2 (pt) 2018-09-25
CA2853412A1 (en) 2013-05-02
KR101961508B1 (ko) 2019-03-25
IL232219A0 (en) 2014-06-30
AU2012327211A1 (en) 2013-05-23
WO2013061163A3 (en) 2014-03-06
US11091540B2 (en) 2021-08-17
CA3112082A1 (en) 2013-05-02
IL232219B (en) 2019-11-28
US20170152308A1 (en) 2017-06-01
EP2771359B1 (en) 2021-05-19
ES2883212T3 (es) 2021-12-07
US20140255304A1 (en) 2014-09-11
MX2014005048A (es) 2014-11-10
US20200017577A1 (en) 2020-01-16
US9587014B2 (en) 2017-03-07
MX2018008680A (es) 2023-04-18
IL270223B (en) 2021-05-31
JP2019022500A (ja) 2019-02-14
MX357678B (es) 2018-07-19
CN104159918A (zh) 2014-11-19
CN104159918B (zh) 2019-09-13
EA201490825A1 (ru) 2015-01-30
AU2012327211C9 (en) 2016-11-17
KR102032080B1 (ko) 2019-10-15
JP6652609B2 (ja) 2020-02-26
KR20180132977A (ko) 2018-12-12
BR112014010161B1 (pt) 2022-02-08
PH12014500940A1 (en) 2019-06-26
CL2014001074A1 (es) 2015-01-09
EA201490825A8 (ru) 2016-09-30
EA032003B1 (ru) 2019-03-29
AU2012327211C1 (en) 2016-09-15

Similar Documents

Publication Publication Date Title
JP6417451B2 (ja) Ｔｄｐ−４３に特異的な結合分子
US20210238265A1 (en) Human Anti-Tau Antibodies
US20200262895A1 (en) Human anti-tau antibodies
AU2012327211B9 (en) TDP-43 specific binding molecules
DK2370466T3 (en) Humane anti-alpha-synuclein-autoantistoffer
HK40069392A (en) Tdp-43 specific binding molecules
NZ709976B2 (en) Human anti-tau antibodies
HK1201846B (en) Tdp-43 specific binding molecules

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150903

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150903

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160620

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160920

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170823

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20170914

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20171011

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20171106

R150 Certificate of patent or registration of utility model

Ref document number: 6240611

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees